Psoriasis Clinical Trials in San Antonio

Showing 101-120 of 155 trials

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

NCT02515097

This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Plaque Psoriasis

Bausch Health Americas, Inc.213 participantsStarted Nov 2015

Santa Ana, California, United States • Boynton Beach, Florida, United States • Clearwater, Florida, United States +12 more locations

TERMINATEDPhase 3< 1 mile

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603

The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses

Moderate to Severe Plaque Psoriasis

Bausch Health Americas, Inc.1,831 participantsStarted Aug 2012

Birmingham, Alabama, United States • Tucson, Arizona, United States • Hot Springs, Arkansas, United States +150 more locations

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Psoriasis Trials in Other Cities

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

A Study in Participants With Moderate to Severe Psoriasis

Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study

A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

A Study of Ixekizumab in Participants With Plaque Psoriasis

Other Conditions in San Antonio